Esophageal Cancer and Barrett's Esophagus. (Record no. 101197)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11064nam a22005173i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC4037303 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729130037.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2015 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118655184 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781118655207 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC4037303 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL4037303 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11111633 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL826461 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)904400113 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC280.E8 -- .S537 2015eb |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99432 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Sharma, Prateek. |
| 245 10 - TITLE STATEMENT | |
| Title | Esophageal Cancer and Barrett's Esophagus. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 3rd ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2015. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2015. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (502 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro -- Title Page -- Copyright -- Table of Contents -- List of contributors -- Preface -- Chapter 1: Epidemiology of esophageal carcinoma -- 1.1 The incidence and mortality related to esophageal cancer -- 1.2 Mortality -- 1.3 Risk factors for EA -- References -- Chapter 2: Barrett's esophagus: definition and diagnosis -- 2.1 Introduction -- 2.2 Early history of Barrett's esophagus -- 2.3 Early reports on the histology of Barrett's esophagus -- 2.4 Identification of the gastroesophageal junction -- 2.5 Recognition of short segment Barrett's esophagus -- 2.6 Intestinal metaplasia and adenocarcinoma of the esophagus -- 2.7 The problem of cardiac mucosa -- 2.8 Definition of Barrett's esophagus -- 2.9 Diagnostic criteria for Barrett's esophagus -- 2.10 Intestinal metaplasia at the GEJ -- References -- Chapter 3: Epidemiology and prevalence of Barrett's esophagus -- 3.1 Introduction -- 3.2 BE prevalence -- 3.3 BE incidence -- 3.4 Etiology and risk factors for BE -- 3.5 Neoplastic progression risk in BE -- 3.6 Conclusions -- References -- Chapter 4: Esophageal adenocarcinoma: risk factors -- 4.1 Introduction -- 4.2 Gastroesophageal reflux disease (GERD) -- 4.3 Barrett's esophagus (BE) -- 4.4 Obesity -- 4.5 Smoking -- 4.6 Alcohol -- 4.7 Dietary factors -- 4.8 Medication use -- 4.9 H. pylori -- 4.10 Demographics -- 4.11 Summary -- References -- Chapter 5: Esophageal motility abnormalities in Barrett's esophagus -- 5.1 Introduction -- 5.2 Antireflux barrier -- 5.3 Lower esophageal sphincter -- 5.4 Diaphragmatic sphincter and hiatal hernia -- 5.5 Mechanical properties of the relaxed EGJ -- 5.6 Esophageal clearance -- 5.7 Peristaltic dysfunction -- 5.8 Gastric emptying and duodenogastroesophageal reflux -- 5.9 Therapy of motor abnormalities in Barrett's esophagus -- 5.10 Conclusion -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 6: Molecular biology of Barrett's esophagus and esophageal adenocarcinoma -- Abbreviations used in this chapter -- 6.1 Introduction -- 6.2 Genetic and host susceptibility -- 6.3 Environmental factors contributing to the development of BE -- 6.4 Genomic instability mutations and copy number changes in candidate genes -- 6.5 The advent of next generation sequencing -- 6.6 Future directions and conclusions -- References -- Chapter 7: Histology of Barrett's esophagus: metaplasia and dysplasia -- 7.1 Introduction -- 7.2 Normal anatomy and histology -- 7.3 Histology of Barrett's esophagus -- 7.4 Intestinal metaplasia of the EGJ -- 7.5 Barrett's esophagus-related dysplasia -- 7.6 Intramucosal adenocarcinoma (IMC) -- 7.7 Submucosal adenocarcinoma -- 7.8 Morphologic types of dysplasia -- 7.9 Sampling error and observer variation in Barrett's esophagus-related dysplasia -- 7.10 Surrogate biomarkers for assessing risk of esophageal adenocarcinoma -- References -- Chapter 8: Helicobacter pylori and esophageal neoplasia -- 8.1 Introduction -- 8.2 H. pylori infection - gastritis pattern and gastric physiology with impact on gastroesophageal reflux disease -- 8.3 Epidemiological studies - GERD symptoms, erosive esophagitis and H. pylori -- 8.4 H. pylori, Barrett's esophagus and esophageal adenocarcinoma -- 8.5 H. pylori eradication and GERD -- 8.6 H. pylori and esophageal squamous cell carcinoma -- 8.7 Conclusions -- References -- Chapter 9: Screening and surveillance -- 9.1 Introduction -- 9.2 Screening -- 9.3 Surveillance -- 9.4 Conclusion -- References -- Chapter 10: New surface imaging technologies for dysplasia and cancer detection -- 10.1 Introduction -- 10.2 Surface imaging in Barrett's esophagus -- 10.3 Surface imaging for esophageal squamous cell carcinoma -- 10.4 Summary -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 11: New cellular imaging technologies for dysplasia and cancer detection -- 11.1 Introduction -- 11.2 Confocal laser endomicroscopy -- 11.3 Endocytoscopy -- 11.4 Optical coherence tomography -- 11.5 Molecular imaging in Barrett's -- 11.6 Conclusion -- References -- Chapter 12: The role of endoscopic ultrasound in esophageal cancer -- 12.1 Background -- 12.2 Equipment -- 12.3 Visualized EUS anatomy -- 12.4 Obstacles to accurate EUS staging -- 12.5 Esophageal cancer staging and impact on treatment intervention -- 12.6 T staging -- 12.7 N staging -- 12.8 M staging -- 12.9 Restaging after chemoradiotherapy and surveillance for disease recurrence -- 12.10 Conclusion/summary -- References -- Chapter 13: Staging of esophageal adenocarcinoma by CT, PET, and other modalities -- 13.1 Introduction -- 13.2 Endoscopic staging -- 13.3 Staging by external ultrasonography -- 13.4 Staging by radiological examinations -- 13.5 Staging by positron emission tomography (PET) -- 13.6 The value of FDG-PET to predict response to pre-operative treatment -- 13.7 Conclusion: summary of recommended staging procedures -- References -- Chapter 14: Medical management of Barrett's esophagus -- 14.1 Introduction -- 14.2 Assessment of symptoms -- 14.3 Acid suppressive therapies in management of reflux symptoms -- 14.4 Normalization of intraesophageal acid exposure -- 14.5 Management of erosive esophagitis -- 14.6 Maintenance of healed mucosa after endoscopic eradication therapies -- 14.7 Conclusions -- References -- Chapter 15: Thermal therapies and photodynamic therapy for early esophageal neoplasia -- 15.1 Introduction -- 15.2 Photodynamic therapy -- 15.3 Argon plasma coagulation -- 15.4 Cryotherapy -- 15.5 Conclusion -- References -- Chapter 16: RFA for early esophageal neoplasia -- 16.1 Background -- 16.2 Device and procedural technique. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 16.3 Efficacy and durability of radiofrequency ablation -- 16.4 Initial treatment response to RFA and risk factors for failed ablation -- 16.5 Endoscopic mucosal resection in combination with radiofrequency ablation -- 16.6 Safety and tolerability of radiofrequency ablation -- 16.7 Subsquamous intestinal metaplasia after radiofrequency ablation -- 16.8 Surveillance following radiofrequency ablation -- 16.9 Conclusions -- References -- Chapter 17: The role of endoscopic cryotherapy for treatment and palliation -- 17.1 Introduction -- 17.2 Cryotherapy mechanisms of tissue injury -- 17.3 Types of cryotherapy: devices, dosing, and endoscopic application -- 17.4 Efficacy and safety in Barrett's esophagus -- 17.5 Cryotherapy for the treatment of esophageal carcinoma -- 17.6 Summary and future directions -- References -- Chapter 18: Endoscopic resection -- 18.1 Introduction -- 18.2 ER techniques -- 18.3 ER in HGIN and early Barrett's cancer -- 18.4 ER of submucosal Barrett's adenocarcinoma -- 18.5 Conclusions -- References -- Chapter 19: Endoscopic submucosal dissection -- 19.1 Introduction -- 19.2 Indications of ESD for esophageal cancer -- 19.3 Preoperative examination -- 19.4 Techniques of ESD [19-22] for esophageal cancer -- 19.5 Complications -- 19.6 Sedation and anesthesia -- 19.7 Results -- 19.8 Training -- 19.9 Conclusion -- References -- Chapter 20: Surgical therapy of early esophageal cancer -- 20.1 Introduction -- 20.2 "Early" esophageal cancer -- 20.3 Indication of surgical resection for early esophageal adenocarcinoma -- 20.4 Strategy of surgical resection for early esophageal adenocarcinoma -- 20.5 Choice of surgical approach and outcomes -- 20.6 Discussion -- 20.7 Conclusion -- References -- Chapter 21: Chemoprevention: can we prevent esophageal cancer? -- 21.1 Overview -- 21.2 The effect of aspirin on cancer prevention. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 21.3 Risks and adverse effects of aspirin -- 21.4 The role of aspirin in reflux disease -- 21.5 Risk-benefits of aspirin -- 21.6 AspECT trial -- References -- Chapter 22: Selection of patients for cancer prevention and eradication -- 22.1 Introduction -- 22.2 Patient factors -- 22.3 Cancer risk and grade of dysplasia -- 22.4 Baseline quality measures -- 22.5 The lesion -- 22.6 Predictors of response -- 22.7 Predictors of initial response to therapy -- 22.8 Future considerations -- 22.9 Conclusions -- References -- Chapter 23: Combined modality therapy in locally advanced esophageal cancer -- 23.1 Introduction -- 23.2 Pre-operative chemotherapy -- 23.3 Post-operative therapy -- 23.4 Chemoradiation for medically inoperably patients -- 23.5 Pre-operative chemoradiation -- 23.6 Pre-operative chemoradiation vs. chemotherapy -- 23.7 Definitive vs. pre-operative chemoradiation -- 23.8 Newer chemoradiation regimens -- 23.9 Targeted therapies -- 23.10 Positron emission tomography-directed therapy -- 23.11 Conclusion -- References -- Chapter 24: Surgery in locally advanced esophageal cancer -- 24.1 Introduction -- 24.2 Chemotherapy, chemoradiation and surgical complications -- 24.3 Technical considerations -- 24.4 Risks of salvage surgery -- 24.5 Conclusion -- References -- Chapter 25: Radiation therapy for locally advanced esophageal cancer -- 25.1 Introduction -- 25.2 Definitive therapy in unresectable locally advanced esophageal cancer -- 25.3 Trimodality therapy -- 25.4 Techniques of radiation therapy -- 25.5 Conclusions -- References -- Chapter 26: Systemic therapy and targeted agents in advanced esophageal cancer -- 26.1 Introduction -- 26.2 Chemotherapy -- 26.3 Targeted therapy -- 26.4 Future directions -- 26.5 Conclusions -- References -- Chapter 27: Role of endoscopy and nutritional support in advanced esophageal cancer -- 27.1 Introduction. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 27.2 Nutritional support in advanced esophageal cancer. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Esophageal Neoplasms. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sampliner, Richard. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ilson, David. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Sharma, Prateek |
| Title | Esophageal Cancer and Barrett's Esophagus |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2015 |
| International Standard Book Number | 9781118655207 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4037303">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=4037303</a> |
| Public note | Click to View |
No items available.